Brief: Odonate Therapeutics Initiates Cohort 3 Of Contessa Trio for Tesetaxel Monotherapy In Metastatic Breast Cancer Patients
07/12/2020 13:45
Dec 7 (Reuters) - Odonate Therapeutics Inc ODT.O :
* ODONATE THERAPEUTICS INITIATES COHORT 3 OF CONTESSA TRIO
TO
EVALUATE TESETAXEL MONOTHERAPY IN PATIENTS WITH METASTATIC
BREAST CANCER
Source text for Eikon: ID:nBw9J8XWZa
Further company coverage: ODT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Odonate
See all newsBrief: Odonate Announces Expected Delisting Of Its Stock
Brief: Odonate Therapeutics Announces Planned Return Of Capital To Stockholders Through Share Repurchase Plan
Brief: Odonate Therapeutics Announces Quarterly Loss Per Share Of $0.58
Odonate Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Odonate Therapeutics Inc expected to post a loss of 33 cents a share - Earnings Preview